EA201792517A1 - Производные бензоимидазола в качестве ингибиторов pad4 - Google Patents

Производные бензоимидазола в качестве ингибиторов pad4

Info

Publication number
EA201792517A1
EA201792517A1 EA201792517A EA201792517A EA201792517A1 EA 201792517 A1 EA201792517 A1 EA 201792517A1 EA 201792517 A EA201792517 A EA 201792517A EA 201792517 A EA201792517 A EA 201792517A EA 201792517 A1 EA201792517 A1 EA 201792517A1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzoimidazole
derivatives
pad4 inhibitors
lupus erythematosus
pad4
Prior art date
Application number
EA201792517A
Other languages
English (en)
Other versions
EA033680B1 (ru
Inventor
Доминик Аманс
Стивен Джон Аткинсон
Майкл Дэвид Баркер
Мэттью Кэмпбелл
Хава Диалло
Клемент Дуалт
Нил Стюарт Гартон
Джон Лиддл
Джессика Фанни Рено
Роберт Джон Шеппард
Энн Луис Уолкер
Кристофер Роланд Уэллавей
Дэвид Мэттью Уилсон
Original Assignee
Глаксосмиткляйн Интеллекчуал Проперти Девелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмиткляйн Интеллекчуал Проперти Девелопмент Лимитед filed Critical Глаксосмиткляйн Интеллекчуал Проперти Девелопмент Лимитед
Publication of EA201792517A1 publication Critical patent/EA201792517A1/ru
Publication of EA033680B1 publication Critical patent/EA033680B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Abstract

Соединение формулы (I)где X, Y, Rи R-Rимеют значение, определённое в данной заявке, и его соли являются ингибиторами PAD4 и могут применяться в лечении различных заболеваний, например ревматоидного артрита, васкулита, системной красной волчанки, язвенного колита, ракового заболевания, муковисцидоза, астмы, кожной формы красной волчанки и псориаза.
EA201792517A 2015-05-21 2016-05-19 Производные бензоимидазола в качестве ингибиторов pad4 EA033680B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562164906P 2015-05-21 2015-05-21
PCT/IB2016/000761 WO2016185279A1 (en) 2015-05-21 2016-05-19 Benzoimidazole derivatives as pad4 inhibitors

Publications (2)

Publication Number Publication Date
EA201792517A1 true EA201792517A1 (ru) 2018-04-30
EA033680B1 EA033680B1 (ru) 2019-11-15

Family

ID=56235853

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792517A EA033680B1 (ru) 2015-05-21 2016-05-19 Производные бензоимидазола в качестве ингибиторов pad4

Country Status (15)

Country Link
US (2) US10407407B2 (ru)
EP (1) EP3298003B1 (ru)
JP (1) JP6703553B2 (ru)
KR (1) KR20180005250A (ru)
CN (1) CN107849015B (ru)
AR (1) AR106863A1 (ru)
AU (1) AU2016264958B2 (ru)
BR (1) BR112017024678A2 (ru)
CA (2) CA2986199C (ru)
EA (1) EA033680B1 (ru)
ES (1) ES2945314T3 (ru)
IL (2) IL255666A (ru)
MX (1) MX2017014714A (ru)
TW (1) TW201706263A (ru)
WO (1) WO2016185279A1 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
EP3419969B1 (en) * 2016-02-23 2019-12-18 Padlock Therapeutics, Inc. Heteroaryl inhibitors of pad4
EP3490989B1 (en) 2016-07-27 2020-09-09 Padlock Therapeutics, Inc. Covalent inhibitors of pad4
JP7118951B2 (ja) 2016-09-12 2022-08-16 パドロック・セラピューティクス・インコーポレイテッド Ｐａｄ４のヘテロアリール阻害剤
NZ762985A (en) * 2017-09-22 2024-03-22 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
HUE061607T2 (hu) * 2017-10-18 2023-07-28 Jubilant Epipad LLC Imidazopiridin vegyületek mint PAD inhibitorok
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
EP3704120B1 (en) 2017-11-24 2024-03-06 Jubilant Episcribe LLC Heterocyclic compounds as prmt5 inhibitors
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
EP3746430A4 (en) 2018-02-02 2021-11-03 Padforward LLC INHIBITORS OF PROTEIN ARGININE DEIMINASES
BR112020018610A2 (pt) 2018-03-13 2020-12-29 Jubilant Prodel LLC Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas
HRP20230388T1 (hr) 2018-03-22 2023-06-23 F. Hoffmann - La Roche Ag Inhibitori oksazin monoacilglicerol lipaze (magl)
CN112789087A (zh) * 2018-08-08 2021-05-11 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
MX2021001471A (es) * 2018-08-08 2021-04-28 Bristol Myers Squibb Co Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
EA202190462A1 (ru) 2018-08-08 2021-06-03 Бристол-Маерс Сквибб Компани Индольные и азаиндольные ингибиторы ферментов pad
EP3837263A1 (en) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors
MA53220A (fr) 2018-08-13 2021-11-17 Hoffmann La Roche Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
EP3883936B1 (en) 2018-11-22 2023-07-12 F. Hoffmann-La Roche AG New heterocyclic compounds
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
AU2020354414A1 (en) 2019-09-24 2022-02-17 F. Hoffmann-La Roche Ag New heterocyclic monoacylglycerol lipase (MAGL) inhibitors
AR120029A1 (es) 2019-09-24 2022-01-26 Hoffmann La Roche Compuestos heterocíclicos
CN114514233A (zh) 2019-09-24 2022-05-17 豪夫迈·罗氏有限公司 用于单酰基甘油脂肪酶(magl)的荧光探针
TW202115083A (zh) * 2019-09-27 2021-04-16 大陸商南京藥捷安康生物科技有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
JP2023512557A (ja) * 2020-02-06 2023-03-27 ブリストル－マイヤーズ スクイブ カンパニー 免疫抑制剤として有用な大環状ｐａｄ４阻害剤
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
PE20230488A1 (es) * 2020-04-30 2023-03-21 Gilead Sciences Inc Inhibidores macrociclicos de las peptidilarginina deiminasas
WO2022034616A1 (en) * 2020-08-12 2022-02-17 Jubilant Epipad LLC Method and compound for use, in treating and/or preventing netosis
WO2022140390A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
WO2023083365A1 (en) * 2021-11-15 2023-05-19 Qilu Regor Therapeutics Inc. Pad4 inhibitors and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
CA2361954C (en) 1995-04-14 2003-07-08 Smithkline Beecham Corporation Metered dose inhaler for albuterol
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
EP1699512B1 (en) 2003-11-03 2012-06-20 Glaxo Group Limited A fluid dispensing device
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
ES2882797T3 (es) * 2009-04-02 2021-12-02 Merck Serono Sa Inhibidores de dihidroorotato deshidrogenasa
PL3001903T3 (pl) * 2009-12-21 2018-03-30 Samumed, Llc 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne
PL2877467T3 (pl) * 2012-07-26 2017-08-31 Glaxo Group Limited 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4

Also Published As

Publication number Publication date
EP3298003B1 (en) 2023-04-19
AU2016264958B2 (en) 2020-10-29
IL255666A (en) 2018-01-31
MX2017014714A (es) 2018-01-25
US20180297983A1 (en) 2018-10-18
BR112017024678A2 (pt) 2018-07-31
AU2016264958A1 (en) 2017-12-07
ES2945314T3 (es) 2023-06-30
JP6703553B2 (ja) 2020-06-03
EP3298003A1 (en) 2018-03-28
CA2986199A1 (en) 2016-11-24
EA033680B1 (ru) 2019-11-15
CN107849015B (zh) 2021-03-19
US20200095227A1 (en) 2020-03-26
US10407407B2 (en) 2019-09-10
CA2986199C (en) 2023-07-18
AR106863A1 (es) 2018-02-28
CA3199601A1 (en) 2016-11-24
JP2018520105A (ja) 2018-07-26
TW201706263A (zh) 2017-02-16
WO2016185279A1 (en) 2016-11-24
IL278916A (en) 2021-01-31
US10815218B2 (en) 2020-10-27
CN107849015A (zh) 2018-03-27
KR20180005250A (ko) 2018-01-15

Similar Documents

Publication Publication Date Title
EA201792517A1 (ru) Производные бензоимидазола в качестве ингибиторов pad4
CY1121831T1 (el) Παραγωγα θειενο [2,3-c] πυρρολ-4-ονης ως αναστολεις της erk
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
PH12016502099A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
MA40076A (fr) Inhibiteurs de syk
EA201591317A1 (ru) Соединения тубулизина, способы их получения и применение
DK3842429T3 (da) Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
DK3079725T3 (da) Administration, brug og terapeutiske anvendelser af crispr-cas-systemerne og sammensætninger til genomredigering
MY197626A (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
MX2017013880A (es) Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos.
MX2019009266A (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer.
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
MX2019009351A (es) Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cancer.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
EP3471712A4 (en) ALDH SMALL MOLECULE INHIBITORS AND USES THEREOF
EP3245204A4 (en) Small molecules for the treatment of primary cancer and cancer metastasis
EP3628374A3 (en) Bcl-3 inhibitors
DK3454879T3 (da) Hidtil ukendte forbindelser og farmaceutisk anvendelse deraf i behandlingen af kræft
EP3261638A4 (en) Pyrimidine derivatives as kinase inhibitors and their therapeutical applications

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM